Cargando…

Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study

BACKGROUND: Due to the emergence of Mycobacterium tuberculosis (M.tb) clinical isolates resistant to most potent first-line drugs (FLD), second-line drugs (SLD) are being prescribed more frequently. We explore the genetic characteristics and molecular mechanisms of M.tb isolates phenotypically resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Sokleaph, Hide, Mallorie, Pheng, Sok Heng, Kerléguer, Alexandra, Delvallez, Gauthier, Sam, Sophan, Mao, Tan Eang, Nguyen, Thi Van Anh, Bañuls, Anne-Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982564/
https://www.ncbi.nlm.nih.gov/pubmed/33762833
http://dx.doi.org/10.2147/IDR.S289907
_version_ 1783667746104410112
author Cheng, Sokleaph
Hide, Mallorie
Pheng, Sok Heng
Kerléguer, Alexandra
Delvallez, Gauthier
Sam, Sophan
Mao, Tan Eang
Nguyen, Thi Van Anh
Bañuls, Anne-Laure
author_facet Cheng, Sokleaph
Hide, Mallorie
Pheng, Sok Heng
Kerléguer, Alexandra
Delvallez, Gauthier
Sam, Sophan
Mao, Tan Eang
Nguyen, Thi Van Anh
Bañuls, Anne-Laure
author_sort Cheng, Sokleaph
collection PubMed
description BACKGROUND: Due to the emergence of Mycobacterium tuberculosis (M.tb) clinical isolates resistant to most potent first-line drugs (FLD), second-line drugs (SLD) are being prescribed more frequently. We explore the genetic characteristics and molecular mechanisms of M.tb isolates phenotypically resistant to SLD, including pre-extensively drug-resistant (pre-XDR) and extensively drug-resistant (XDR) isolates. METHODS: Drug-resistant (DR) M.tb isolates collected from 2012 to 2017 were tested using sequencing and phenotypic drug susceptibility testing. Genotypes were determined to explore their links with SLD resistance patterns. RESULTS: Of the 272 DR M.tb isolates, 6 non-multidrug resistant (non-MDR) isolates were fluoroquinolones (FQ)-resistant, 3 were XDR and 16 were pre-XDR (14 resistant to FQ and 2 to second-line injectable drugs). The most frequent mutations in FQ-resistant and second-line injectable drugs resistant isolates were gyrA D94G (15/23) and rrs a1401g (3/5), respectively. Seventy-five percent of pre-XDR isolates and 100% of XDR isolates harbored mutations conferring resistance to pyrazinamide. All XDR isolates belonged to the Beijing genotype, of which one, named XDR+, was resistant to all drugs tested. One cluster including pre-XDR and XDR isolates was observed. CONCLUSION: This is the first description of SLD resistance in Cambodia. The data suggest that the proportion of XDR and pre-XDR isolates remains low but is on the rise compared to previous reports. The characterization of the XDR+ isolate in a patient who refused treatment underlines the risk of transmission in the population. In addition, genotypic results show, as expected, that the Beijing family is the main involved in pre-XDR and XDR isolates and that the spread of the Beijing pre-XDR strain is capable of evolving into XDR strain. This study strongly indicates the need for rapid interventions in terms of diagnostic and treatment to prevent the spread of the pre-XDR and XDR strains and the emergence of more resistant ones.
format Online
Article
Text
id pubmed-7982564
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79825642021-03-23 Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study Cheng, Sokleaph Hide, Mallorie Pheng, Sok Heng Kerléguer, Alexandra Delvallez, Gauthier Sam, Sophan Mao, Tan Eang Nguyen, Thi Van Anh Bañuls, Anne-Laure Infect Drug Resist Original Research BACKGROUND: Due to the emergence of Mycobacterium tuberculosis (M.tb) clinical isolates resistant to most potent first-line drugs (FLD), second-line drugs (SLD) are being prescribed more frequently. We explore the genetic characteristics and molecular mechanisms of M.tb isolates phenotypically resistant to SLD, including pre-extensively drug-resistant (pre-XDR) and extensively drug-resistant (XDR) isolates. METHODS: Drug-resistant (DR) M.tb isolates collected from 2012 to 2017 were tested using sequencing and phenotypic drug susceptibility testing. Genotypes were determined to explore their links with SLD resistance patterns. RESULTS: Of the 272 DR M.tb isolates, 6 non-multidrug resistant (non-MDR) isolates were fluoroquinolones (FQ)-resistant, 3 were XDR and 16 were pre-XDR (14 resistant to FQ and 2 to second-line injectable drugs). The most frequent mutations in FQ-resistant and second-line injectable drugs resistant isolates were gyrA D94G (15/23) and rrs a1401g (3/5), respectively. Seventy-five percent of pre-XDR isolates and 100% of XDR isolates harbored mutations conferring resistance to pyrazinamide. All XDR isolates belonged to the Beijing genotype, of which one, named XDR+, was resistant to all drugs tested. One cluster including pre-XDR and XDR isolates was observed. CONCLUSION: This is the first description of SLD resistance in Cambodia. The data suggest that the proportion of XDR and pre-XDR isolates remains low but is on the rise compared to previous reports. The characterization of the XDR+ isolate in a patient who refused treatment underlines the risk of transmission in the population. In addition, genotypic results show, as expected, that the Beijing family is the main involved in pre-XDR and XDR isolates and that the spread of the Beijing pre-XDR strain is capable of evolving into XDR strain. This study strongly indicates the need for rapid interventions in terms of diagnostic and treatment to prevent the spread of the pre-XDR and XDR strains and the emergence of more resistant ones. Dove 2021-03-17 /pmc/articles/PMC7982564/ /pubmed/33762833 http://dx.doi.org/10.2147/IDR.S289907 Text en © 2021 Cheng et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Cheng, Sokleaph
Hide, Mallorie
Pheng, Sok Heng
Kerléguer, Alexandra
Delvallez, Gauthier
Sam, Sophan
Mao, Tan Eang
Nguyen, Thi Van Anh
Bañuls, Anne-Laure
Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study
title Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study
title_full Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study
title_fullStr Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study
title_full_unstemmed Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study
title_short Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study
title_sort resistance to second-line anti-tb drugs in cambodia: a phenotypic and genetic study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982564/
https://www.ncbi.nlm.nih.gov/pubmed/33762833
http://dx.doi.org/10.2147/IDR.S289907
work_keys_str_mv AT chengsokleaph resistancetosecondlineantitbdrugsincambodiaaphenotypicandgeneticstudy
AT hidemallorie resistancetosecondlineantitbdrugsincambodiaaphenotypicandgeneticstudy
AT phengsokheng resistancetosecondlineantitbdrugsincambodiaaphenotypicandgeneticstudy
AT kerlegueralexandra resistancetosecondlineantitbdrugsincambodiaaphenotypicandgeneticstudy
AT delvallezgauthier resistancetosecondlineantitbdrugsincambodiaaphenotypicandgeneticstudy
AT samsophan resistancetosecondlineantitbdrugsincambodiaaphenotypicandgeneticstudy
AT maotaneang resistancetosecondlineantitbdrugsincambodiaaphenotypicandgeneticstudy
AT nguyenthivananh resistancetosecondlineantitbdrugsincambodiaaphenotypicandgeneticstudy
AT banulsannelaure resistancetosecondlineantitbdrugsincambodiaaphenotypicandgeneticstudy